Genentech, Texas Biotech deal

GNE and TXB (Houston) extended to June 30, 1997, their agreement covering the development of Novastan ( argatroban injection) to provide TXB more time to file an NDA.

TXB is developing the drug to treat heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), as well as for adjunctive use with thrombolytic therapy for acute myocardial infarction. Novastan is in a pivotal trial in the U.S. and in comparison with an antibiotic, ancrod, in Canada. ...